AC Immune Amended Its 2018 Agreement With Eli Lilly For Tau Aggregation Inhibitor Drugs For Alzheimer's And Other Neurodegenerative Diseases, AC Immune Will Receive CHF10M
Benzinga Newsdesk 6 months ago
BiotechLarge CapNewsHealth CareGeneral
Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for
Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF1.7 billion, plus tiered percentage royalty payments in the low double digits, as previously disclosed.